Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD
See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG
To return to the list of conditions and links to their rpeorts go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html
Study Counts
| Total_Studies |
2345 |
| interventional |
1641 |
| Observational |
638 |
| Registry |
66 |
Interventional Trials
Intervention Type
| Device |
317 |
| Other |
272 |
| Behavioral |
214 |
| Drug |
203 |
| Procedure |
167 |
| Drug|placebo |
144 |
| Device|Other |
50 |
| Biological |
39 |
| Behavioral|Other |
26 |
| Device|Procedure |
21 |
| Device|Drug |
16 |
| Drug|Other |
16 |
| Drug|Procedure |
14 |
| Dietary Supplement |
13 |
| Diagnostic Test |
12 |
| Dietary Supplement|placebo |
12 |
| Other|Procedure |
12 |
| Behavioral|Device |
7 |
| Biological|placebo |
7 |
| Behavioral|Drug |
6 |
| Combination Product |
6 |
| Behavioral|placebo |
5 |
| Biological|Other |
5 |
| Biological|Procedure |
5 |
| Drug|Other|placebo |
5 |
| Drug|placebo|Procedure |
4 |
| Other|placebo |
4 |
| Biological|Device |
3 |
| Biological|Drug |
3 |
| Device|placebo |
3 |
| Drug|Other|Procedure |
3 |
| Radiation |
3 |
| Behavioral|Drug|placebo |
2 |
| Device|Drug|Procedure |
2 |
| placebo|Procedure |
2 |
| Behavioral|Device|Procedure |
1 |
| Behavioral|Diagnostic Test |
1 |
| Behavioral|Drug|Procedure |
1 |
| Behavioral|placebo|Procedure |
1 |
| Biological|Diagnostic Test |
1 |
| Biological|Drug|placebo|Procedure |
1 |
| Biological|Drug|Procedure |
1 |
| Combination Product|Device |
1 |
| Combination Product|Other |
1 |
| Device|Diagnostic Test |
1 |
| Device|Diagnostic Test|Other |
1 |
| Device|Drug|Other|Procedure |
1 |
| Dietary Supplement|Drug |
1 |
| Dietary Supplement|Other |
1 |
| Drug|Radiation |
1 |
| Genetic |
1 |
| placebo |
1 |
| Procedure|Radiation |
1 |
Count of Studies by Intervention (normalized and mapped)
Interventions over Time
Weekly studies for each intervention
Studies by Country
| United States |
728 |
| NA |
98 |
| Canada |
97 |
| China |
59 |
| France |
56 |
| United Kingdom |
45 |
| Spain |
38 |
| Denmark |
35 |
| Korea, Republic of |
34 |
| Sweden |
34 |
| Germany |
32 |
| Brazil |
25 |
| Italy |
23 |
| Switzerland |
22 |
| Norway |
20 |
| Turkey |
20 |
| Egypt |
19 |
| United States|Canada |
19 |
| Taiwan |
15 |
| Finland |
13 |
| Israel |
12 |
| Netherlands |
12 |
| India |
10 |
| Thailand |
9 |
| Belgium |
8 |
| Iran, Islamic Republic of |
8 |
| Poland |
8 |
| Malaysia |
7 |
| Pakistan |
7 |
| Hong Kong |
6 |
| Australia |
5 |
| Austria |
5 |
| Japan |
5 |
| Mexico |
4 |
| Russian Federation |
4 |
| South Africa |
4 |
| Colombia |
3 |
| Greece |
3 |
| Iceland |
3 |
| Slovenia |
3 |
| Argentina |
2 |
| Australia|New Zealand |
2 |
| Chile |
2 |
| Congo |
2 |
| Hungary |
2 |
| Iraq |
2 |
| Jordan |
2 |
| New Zealand |
2 |
| Saudi Arabia |
2 |
| Afghanistan |
1 |
| Australia|Austria|Canada|France|Germany|Israel|Singapore|South Africa|United Kingdom |
1 |
| Australia|Finland|France|Germany|Ireland|New Zealand|Saudi Arabia |
1 |
| Australia|France|New Zealand|Qatar|Saudi Arabia|Switzerland |
1 |
| Austria|Bulgaria|Czechia|Finland|Germany|Poland |
1 |
| Austria|Czech Republic|Germany |
1 |
| Austria|France|Germany|Spain|United Kingdom |
1 |
| Austria|France|Spain|Switzerland|United Kingdom |
1 |
| Belgium|France |
1 |
| Belgium|France|Germany |
1 |
| Cameroon |
1 |
| Canada|France|Israel |
1 |
| Canada|Switzerland |
1 |
| China|Taiwan |
1 |
| Cyprus |
1 |
| Czech Republic |
1 |
| Czechia|Germany|Italy|Spain|Switzerland |
1 |
| Denmark|Germany|Netherlands|Norway|United Kingdom |
1 |
| Finland|Norway|Sweden |
1 |
| France|Greece|Latvia|Spain |
1 |
| France|Guadeloupe |
1 |
| Georgia |
1 |
| Germany|Spain|Switzerland |
1 |
| Indonesia |
1 |
| Iraq|Jordan |
1 |
| Ireland |
1 |
| Lebanon |
1 |
| Lithuania |
1 |
| Luxembourg |
1 |
| Netherlands|Switzerland |
1 |
| Panama |
1 |
| Philippines |
1 |
| Portugal |
1 |
| Puerto Rico |
1 |
| Qatar |
1 |
| Rwanda |
1 |
| Singapore |
1 |
| Uganda |
1 |
| Ukraine |
1 |
| United States|Argentina|Australia|Brazil|Canada|Colombia|Czechia|Denmark|France|Germany|India|Italy|Kenya|Peru|Philippines|Poland|South Africa|Spain|United Kingdom |
1 |
| United States|Argentina|Austria|Belgium|China|Czech Republic|Finland|France|Germany|Hungary|Israel|Italy|Malaysia|Netherlands|Romania|Russian Federation|Singapore|Spain|Taiwan|Thailand|United Kingdom |
1 |
| United States|Australia |
1 |
| United States|Australia|Austria|Belgium|Brazil|Canada|China|Finland|France|Germany|Ireland|Italy|New Zealand|Switzerland|United Kingdom |
1 |
| United States|Australia|Belgium|Canada|New Zealand|Spain |
1 |
| United States|Australia|Belgium|Czechia|France|Germany|Italy|Poland|Russian Federation|Spain|Switzerland|United Kingdom |
1 |
| United States|Australia|Canada |
1 |
| United States|Australia|Canada|India|Norway |
1 |
| United States|Australia|Germany|India|United Kingdom |
1 |
| United States|Australia|India|Italy|Romania|Ukraine |
1 |
| United States|Austria|Germany|Israel |
1 |
| United States|Austria|Ireland |
1 |
| United States|Brazil|Canada |
1 |
| United States|Canada|Czech Republic|France|Poland|Spain|United Kingdom |
1 |
| United States|Canada|Germany |
1 |
| United States|Canada|India |
1 |
| United States|Canada|New Zealand |
1 |
| United States|Chile|China|Colombia|Czech Republic|Hong Kong|India|Japan|Philippines|Russian Federation |
1 |
| United States|China |
1 |
| United States|Czechia|Denmark|Sweden |
1 |
| United States|Denmark |
1 |
| United States|Denmark|Germany |
1 |
| United States|Germany|Hungary|Poland |
1 |
| United States|Italy |
1 |
| United States|Japan|Ukraine |
1 |
| United States|Puerto Rico |
1 |
Sites per Study
| 1 |
1291 |
| 2 |
121 |
| 3 |
44 |
| 4 |
28 |
| 5 |
28 |
| 6 |
16 |
| 7 |
11 |
| 8 |
10 |
| 9 |
8 |
| 10 |
7 |
| 11 |
4 |
| 12 |
3 |
| 13 |
6 |
| 14 |
4 |
| 15 |
4 |
| 16 |
5 |
| 17 |
7 |
| 18 |
2 |
| 19 |
2 |
| 20 |
3 |
| 21 |
3 |
| 22 |
1 |
| 24 |
2 |
| 25 |
1 |
| 26 |
1 |
| 27 |
1 |
| 28 |
1 |
| 29 |
3 |
| 30 |
3 |
| 31 |
1 |
| 33 |
1 |
| 34 |
2 |
| 36 |
2 |
| 39 |
1 |
| 41 |
4 |
| 43 |
2 |
| 45 |
1 |
| 66 |
2 |
| 67 |
1 |
| 82 |
1 |
| 105 |
1 |
| 110 |
1 |
| 156 |
1 |
Phase
| N/A |
1084 |
| Phase 2 |
166 |
| Phase 4 |
119 |
| Phase 3 |
89 |
| Phase 1 |
70 |
| Phase 1/Phase 2 |
68 |
| Phase 2/Phase 3 |
31 |
| Early Phase 1 |
14 |
Number of Arms
| 1 |
294 |
| 2 |
1063 |
| 3 |
127 |
| 4 |
51 |
| 5 |
12 |
| 6 |
12 |
| 7 |
1 |
| 8 |
1 |
| 9 |
1 |
| 10 |
1 |
| 11 |
1 |
| 12 |
2 |
| 16 |
1 |
| NA |
74 |
Number of Updates
| 1 |
231 |
| 2 |
268 |
| 3 |
242 |
| 4 |
213 |
| 5 |
163 |
| 6 |
111 |
| 7 |
99 |
| 8 |
86 |
| 9 |
46 |
| 10 |
40 |
| 11 |
20 |
| 12 |
27 |
| 13 |
16 |
| 14 |
13 |
| 15 |
8 |
| 16 |
12 |
| 17 |
6 |
| 18 |
6 |
| 19 |
5 |
| 20 |
7 |
| 21 |
3 |
| 22 |
1 |
| 25 |
2 |
| 26 |
1 |
| 27 |
1 |
| 28 |
1 |
| 29 |
1 |
| 30 |
1 |
| 33 |
1 |
| 45 |
1 |
| 47 |
2 |
| 52 |
1 |
| 53 |
1 |
| 65 |
1 |
| 74 |
1 |
| 77 |
1 |
| 120 |
1 |
| 132 |
1 |
Update History Change Type
| Study Status |
6987 |
1410 |
4.955319 |
| Contacts/Locations |
2980 |
1170 |
2.547009 |
| Recruitment Status |
1916 |
1176 |
1.629252 |
| None (earliest Version on record) |
1641 |
1641 |
1.000000 |
| Study Design |
1322 |
942 |
1.403397 |
| Outcome Measures |
1037 |
665 |
1.559398 |
| Sponsor/Collaborators |
758 |
534 |
1.419476 |
| Eligibility |
751 |
467 |
1.608137 |
| Arms |
743 |
507 |
1.465483 |
| Interventions |
743 |
507 |
1.465483 |
| Study Description |
696 |
469 |
1.484009 |
| Study Identification |
554 |
398 |
1.391960 |
| Oversight |
493 |
415 |
1.187952 |
| Conditions |
252 |
207 |
1.217391 |
| References |
246 |
159 |
1.547170 |
| Results |
204 |
204 |
1.000000 |
| IPDSharing |
197 |
180 |
1.094444 |
| More Information |
151 |
81 |
1.864197 |
| Results Submission Events |
103 |
103 |
1.000000 |
| Documents |
66 |
63 |
1.047619 |
| Baseline Characteristics |
46 |
38 |
1.210526 |
| Reported Adverse Events |
25 |
21 |
1.190476 |
| Participant Flow |
21 |
19 |
1.105263 |
| 2020 Outcome Measures |
2 |
2 |
1.000000 |
| 2020 Study Status |
1 |
1 |
1.000000 |
| 2020Recruitment Status |
1 |
1 |
1.000000 |
| Quality Control Review has not concludedReturned: February 13 |
1 |
1 |
1.000000 |
| Quality Control Review has not concludedReturned: February 18 |
1 |
1 |
1.000000 |
| Quality Control Review has not concludedReturned: June 4 |
1 |
1 |
1.000000 |
| Quality Control Review has not concludedReturned: March 5 |
1 |
1 |
1.000000 |
Enrollment Metrics by Phase
| Min. |
4.00 |
1.000 |
3 |
1.00000 |
2.0000 |
2.0000 |
10.000 |
2.0000 |
| 1st Qu. |
10.00 |
29.000 |
10 |
16.75000 |
33.0000 |
30.5000 |
81.000 |
31.2500 |
| Median |
18.00 |
60.000 |
20 |
27.50000 |
60.0000 |
60.0000 |
187.000 |
65.5000 |
| Mean |
38.50 |
1173.539 |
30 |
44.83824 |
704.1867 |
100.3871 |
1007.545 |
142.4661 |
| 3rd Qu. |
43.75 |
143.000 |
39 |
50.00000 |
120.7500 |
149.0000 |
461.750 |
138.5000 |
| Max. |
201.00 |
949609.000 |
120 |
600.00000 |
100000.0000 |
351.0000 |
28669.000 |
2300.0000 |
Trial Group Type
| Experimental |
1517 |
| Active Comparator |
840 |
| Placebo Comparator |
321 |
| No Intervention |
277 |
| Other |
170 |
| Sham Comparator |
97 |
| NA |
74 |
Intervention Model
| Parallel Assignment |
1089 |
| Single Group Assignment |
379 |
| Crossover Assignment |
114 |
| Factorial Assignment |
39 |
| Sequential Assignment |
13 |
| NA |
7 |
Primary Purpose
| Treatment |
1057 |
| Prevention |
260 |
| Supportive Care |
78 |
| Other |
63 |
| Diagnostic |
58 |
| Basic Science |
40 |
| Health Services Research |
32 |
| NA |
31 |
| Screening |
12 |
| Device Feasibility |
10 |
Observational Studies
Studies by Country
| United States |
238 |
| NA |
59 |
| France |
40 |
| China |
31 |
| Canada |
25 |
| United Kingdom |
25 |
| Switzerland |
19 |
| Germany |
17 |
| Italy |
12 |
| Denmark |
11 |
| Austria |
10 |
| Finland |
10 |
| Israel |
9 |
| Spain |
9 |
| Sweden |
9 |
| Turkey |
9 |
| Taiwan |
8 |
| United States|Canada |
7 |
| Belgium |
6 |
| Korea, Republic of |
6 |
| Netherlands |
6 |
| Czechia |
5 |
| Egypt |
5 |
| India |
5 |
| Brazil |
4 |
| Norway |
4 |
| Ireland |
3 |
| Poland |
3 |
| Australia |
2 |
| Greece |
2 |
| Russian Federation |
2 |
| United States|Germany |
2 |
| United States|Germany|Hungary |
2 |
| Algeria |
1 |
| Argentina |
1 |
| Australia|India|Korea, Republic of|Singapore|Thailand |
1 |
| Austria|Bulgaria|Croatia|France|Germany|Ireland|Italy|Netherlands|Romania|Serbia|Turkey|United Kingdom |
1 |
| Bosnia and Herzegovina |
1 |
| China|Taiwan |
1 |
| Denmark|Norway |
1 |
| Finland|United Kingdom |
1 |
| France|Spain |
1 |
| Germany|Greece|Italy|United Kingdom |
1 |
| Haiti |
1 |
| Iran, Islamic Republic of |
1 |
| Italy|Slovenia|Switzerland|United Kingdom |
1 |
| Jamaica |
1 |
| Jordan |
1 |
| Malaysia |
1 |
| Norway|Sweden |
1 |
| Pakistan |
1 |
| Qatar |
1 |
| Singapore |
1 |
| Slovenia |
1 |
| South Africa |
1 |
| Thailand |
1 |
| United States|Austria|Belgium|Canada|France|Germany|Italy|Netherlands|Spain|Sweden|Switzerland|United Kingdom |
1 |
| United States|Austria|Belgium|Germany|Spain|United Kingdom |
1 |
| United States|Austria|Canada|France|Germany|Spain|Sweden|United Kingdom |
1 |
| United States|Austria|Canada|United Kingdom |
1 |
| United States|Bolivia|Canada|Chile|India|United Kingdom |
1 |
| United States|China|Israel|Norway|Palestinian Territory, occupied|Russian Federation|Sweden |
1 |
| United States|Estonia|Germany|Italy|Lithuania|Netherlands|Norway|Slovenia |
1 |
| United States|Greece|Ireland|Italy|Netherlands|Spain|Switzerland |
1 |
| United States|Hungary |
1 |
| United States|United Kingdom |
1 |
Sites per Study
| 1 |
528 |
| 2 |
36 |
| 3 |
15 |
| 4 |
10 |
| 5 |
8 |
| 6 |
3 |
| 7 |
4 |
| 8 |
2 |
| 9 |
3 |
| 10 |
4 |
| 11 |
1 |
| 12 |
1 |
| 13 |
1 |
| 14 |
1 |
| 15 |
2 |
| 16 |
1 |
| 17 |
3 |
| 18 |
1 |
| 19 |
1 |
| 21 |
2 |
| 22 |
1 |
| 23 |
2 |
| 24 |
1 |
| 28 |
1 |
| 33 |
1 |
| 35 |
1 |
| 39 |
1 |
| 44 |
1 |
| 58 |
1 |
| 371 |
1 |
Number of Updates
| 1 |
110 |
| 2 |
135 |
| 3 |
113 |
| 4 |
60 |
| 5 |
54 |
| 6 |
46 |
| 7 |
22 |
| 8 |
23 |
| 9 |
13 |
| 10 |
12 |
| 11 |
10 |
| 12 |
2 |
| 13 |
3 |
| 14 |
4 |
| 15 |
5 |
| 17 |
1 |
| 18 |
5 |
| 20 |
1 |
| 21 |
4 |
| 22 |
1 |
| 24 |
2 |
| 26 |
1 |
| 28 |
1 |
| 30 |
1 |
| 34 |
1 |
| 35 |
1 |
| 47 |
1 |
| 49 |
1 |
| 59 |
1 |
| 73 |
1 |
| 83 |
1 |
| 100 |
2 |
Update History Change Type
| Study Status |
2682 |
528 |
5.079546 |
| Contacts/Locations |
918 |
387 |
2.372093 |
| None (earliest Version on record) |
638 |
638 |
1.000000 |
| Recruitment Status |
629 |
410 |
1.534146 |
| Study Design |
472 |
334 |
1.413174 |
| Study Description |
346 |
174 |
1.988506 |
| Eligibility |
290 |
175 |
1.657143 |
| Sponsor/Collaborators |
285 |
200 |
1.425000 |
| Outcome Measures |
246 |
180 |
1.366667 |
| Study Identification |
192 |
130 |
1.476923 |
| Groups |
175 |
121 |
1.446281 |
| Interventions |
175 |
121 |
1.446281 |
| Oversight |
115 |
97 |
1.185567 |
| References |
107 |
64 |
1.671875 |
| Conditions |
90 |
74 |
1.216216 |
| IPDSharing |
47 |
44 |
1.068182 |
| Results |
27 |
27 |
1.000000 |
| More Information |
20 |
15 |
1.333333 |
| Results Submission Events |
9 |
9 |
1.000000 |
| Baseline Characteristics |
8 |
6 |
1.333333 |
| Participant Flow |
7 |
5 |
1.400000 |
| Documents |
6 |
5 |
1.200000 |
| Reported Adverse Events |
6 |
5 |
1.200000 |
Enrollment Metrics
| Min |
1.00 |
| 1st Qu |
50.00 |
| Median |
129.00 |
| Mean |
13594.53 |
| 3rd Qu |
400.00 |
| Max |
3255526.00 |
Observation Model
| Cohort |
391 |
| Case-Only |
68 |
| Case-Control |
60 |
| Case Control |
40 |
| Other |
37 |
| NA |
30 |
| Ecologic or Community |
5 |
| Case-Crossover |
4 |
| Defined Population, Natural History |
3 |
Time Perspective
| Prospective |
444 |
| Retrospective |
105 |
| Cross-Sectional |
56 |
| Other |
20 |
| NA |
9 |
| Longitudinal, Prospective |
3 |
| Cross-Sectional, Prospective |
1 |
Registries
Studies by Country
| United States |
17 |
| NA |
8 |
| Korea, Republic of |
4 |
| Sweden |
4 |
| Canada |
3 |
| China |
3 |
| Denmark |
3 |
| Switzerland |
3 |
| Brazil |
2 |
| Egypt |
2 |
| Italy |
2 |
| Kenya |
2 |
| Norway |
2 |
| Turkey |
2 |
| Austria |
1 |
| Belgium |
1 |
| Czech Republic |
1 |
| Ethiopia |
1 |
| Iraq |
1 |
| Israel |
1 |
| Taiwan |
1 |
| Thailand |
1 |
| United States|Australia|Canada|China|Indonesia|Italy|Korea, Republic of|Serbia|Singapore|United Kingdom |
1 |
Sites per Study
| 1 |
57 |
| 2 |
2 |
| 3 |
1 |
| 4 |
1 |
| 12 |
1 |
| 14 |
1 |
| 15 |
1 |
| 18 |
1 |
| 32 |
1 |
Number of Updates
| 1 |
15 |
| 2 |
13 |
| 3 |
21 |
| 4 |
8 |
| 5 |
3 |
| 6 |
1 |
| 7 |
2 |
| 10 |
2 |
| 13 |
1 |
Update History Change Type
| Study Status |
138 |
51 |
2.705882 |
| None (earliest Version on record) |
66 |
66 |
1.000000 |
| Contacts/Locations |
60 |
38 |
1.578947 |
| Recruitment Status |
47 |
34 |
1.382353 |
| Study Design |
37 |
31 |
1.193548 |
| Eligibility |
18 |
14 |
1.285714 |
| Outcome Measures |
16 |
12 |
1.333333 |
| Study Description |
16 |
16 |
1.000000 |
| Sponsor/Collaborators |
11 |
10 |
1.100000 |
| Study Identification |
9 |
8 |
1.125000 |
| Groups |
8 |
7 |
1.142857 |
| Interventions |
8 |
7 |
1.142857 |
| Conditions |
5 |
4 |
1.250000 |
| IPDSharing |
5 |
4 |
1.250000 |
| Oversight |
4 |
4 |
1.000000 |
| References |
4 |
4 |
1.000000 |
| Documents |
2 |
2 |
1.000000 |
| Baseline Characteristics |
1 |
1 |
1.000000 |
| More Information |
1 |
1 |
1.000000 |
| Reported Adverse Events |
1 |
1 |
1.000000 |
| Results |
1 |
1 |
1.000000 |
Enrollment Metrics
| Min |
7.000 |
| 1st Qu |
70.000 |
| Median |
240.000 |
| Mean |
5071.712 |
| 3rd Qu |
1200.000 |
| Max |
175000.000 |
Registry Model
| Cohort |
44 |
| Case-Only |
10 |
| Case-Control |
7 |
| Other |
2 |
| NA |
2 |
| Case Control |
1 |
Time Perspective
| Prospective |
55 |
| Other |
6 |
| Cross-Sectional |
4 |
| NA |
1 |
Follow-up
| 6 Months |
8 |
| 12 Months |
6 |
| 1 Year |
5 |
| 5 Years |
5 |
| 1 Day |
4 |
| 1 Month |
4 |
| 28 Days |
4 |
| 3 Years |
4 |
| 2 Years |
3 |
| 3 Months |
3 |
| 30 Days |
3 |
| 3 Weeks |
2 |
| 1 Week |
1 |
| 120 Days |
1 |
| 14 Days |
1 |
| 14 Months |
1 |
| 16 Years |
1 |
| 2 Months |
1 |
| 2 Weeks |
1 |
| 24 Weeks |
1 |
| 3 Days |
1 |
| 4 Months |
1 |
| 4 Weeks |
1 |
| 4 Years |
1 |
| 5 Weeks |
1 |
| 90 Days |
1 |
| 99 Years |
1 |